Drug Profile


Alternative Names: 1325756; GSK1325756

Latest Information Update: 07 Dec 2016

Price : $50

At a glance

  • Originator GlaxoSmithKline
  • Class
  • Mechanism of Action Interleukin 8B receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Chronic obstructive pulmonary disease; Influenza virus infections

Most Recent Events

  • 05 Oct 2016 GlaxoSmithKline plans a phase II trial for Influenza virus infections (Combination therapy) in Sweden, Mexico, Italy, South Korea, Spain, USA, Romania, Russia, Netherlands and France (IV, Infusion) (NCT02927431)
  • 29 Sep 2016 Preclinical trials in Influenza virus infections in United Kingdom (IV) before September 2016
  • 01 Aug 2016 GlaxoSmithKline completes a phase II trial for Chronic obstructive pulmonary disease in USA and Germany (NCT02130193)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top